Generic Promacta Availability

Last updated on Jul 9, 2025.

See also: Generic Promacta Kit

Promacta is a brand name of eltrombopag, approved by the FDA in the following formulation(s):

PROMACTA (eltrombopag olamine - tablet;oral)

• Manufacturer: NOVARTIS
  Approval date: November 20, 2008
  Strength(s): EQ 25MG ACID ^{[RLD] [AB]}, EQ 50MG ACID ^{[RLD] [AB]}
• Manufacturer: NOVARTIS
  Approval date: September 8, 2009
  Strength(s): EQ 75MG ACID ^{[RLD] [AB]}
• Manufacturer: NOVARTIS
  Approval date: October 20, 2011
  Strength(s): EQ 12.5MG ACID ^{[RLD] [AB]}
• Manufacturer: NOVARTIS
  Approval date: November 16, 2012
  Strength(s): EQ 100MG ACID (discontinued) ^{[RLD] [AB]}

Is there a generic version of Promacta available?

A generic version of Promacta has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Promacta and have been approved by the FDA:

eltrombopag olamine tablet;oral

• Manufacturer: HETERO LABS LTD V
  Approval date: January 17, 2025
  Strength(s): EQ 12.5MG ACID ^[AB], EQ 25MG ACID ^[AB], EQ 50MG ACID ^[AB], EQ 75MG ACID ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Promacta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 3'-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-y- lidene]hy-drazino]-2'-hydroxy-[1,1'-piphenyl]-acid bis-(monoethanolamine)
  Patent 7,547,719
  Issued: June 16, 2009
  Inventor(s): Moore; Stephen
  Assignee(s): SmithKline Beecham Corp. (Philadelphia, PA)
  

  An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid.

  Patent expiration dates:

  • July 13, 2025
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • July 13, 2025
    
    ✓ 
    Patent use: PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • July 13, 2025
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • July 13, 2025
    
    ✓ 
    Patent use: COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • July 13, 2025
    
    ✓ 
    Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
    ✓ 
    Drug substance
    ✓ 
    Drug product
• 3'-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-y- lidene]hy-drazino]-2'-hydroxy-[1,1'-piphenyl]-acid bis-(monoethanolamine)
  Patent 7547719*PED
  Issued: June 16, 2009
  Inventor(s): Moore; Stephen
  Assignee(s): SmithKline Beecham Corp. (Philadelphia, PA)
  

  An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid.

  Patent expiration dates:

  • January 13, 2026
    
    ✓ 
    Pediatric exclusivity
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8,052,993
  Issued: November 8, 2011
  Inventor(s): Muller; Francis X et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1- ,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
    ✓ 
    Drug product
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8052993*PED
  Issued: November 8, 2011
  Inventor(s): Muller; Francis X et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1- ,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • February 1, 2028
    
    ✓ 
    Pediatric exclusivity
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8,052,994
  Issued: November 8, 2011
  Inventor(s): Muller; Francis X. et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
    ✓ 
    Drug product
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8052994*PED
  Issued: November 8, 2011
  Inventor(s): Muller; Francis X. et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • February 1, 2028
    
    ✓ 
    Pediatric exclusivity
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1- '-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8,062,665
  Issued: November 22, 2011
  Inventor(s): Muller; Francis X et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
    ✓ 
    Drug product
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1- '-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8062665*PED
  Issued: November 22, 2011
  Inventor(s): Muller; Francis X et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • February 1, 2028
    
    ✓ 
    Pediatric exclusivity
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8,071,129
  Issued: December 6, 2011
  Inventor(s): Muller; Francis X et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1- ,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
• 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8071129*PED
  Issued: December 6, 2011
  Inventor(s): Muller; Francis X et al.
  Assignee(s): GlaxoSmithKline LLC (Philadelphia, PA)
  

  Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1- ,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • February 1, 2028
    
    ✓ 
    Pediatric exclusivity
• 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8,828,430
  Issued: September 9, 2014
  Inventor(s): Muller Francis X. & Kapsi Shivakumar G
  Assignee(s): GlaxoSmithKline LLC
  

  Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis (monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
    ✓ 
    Drug product
  • August 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
    ✓ 
    Drug product
• 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
  Patent 8828430*PED
  Issued: September 9, 2014
  Inventor(s): Muller Francis X. & Kapsi Shivakumar G
  Assignee(s): GlaxoSmithKline LLC
  

  Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis (monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

  Patent expiration dates:

  • February 1, 2028
    
    ✓ 
    Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • November 16, 2025 - INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer